Se connecter Inscription gratuite

Last updated: 28 May 2024 at 5:36pm EST

Stephanie Lovell Net Worth




The estimated Net Worth of Stephanie Lovell is at least $160 millier dollars as of 22 November 2022. Ms. Lovell owns over 10,557 units of Cyclerion Therapeutics stock worth over $16,999 and over the last 5 years she sold CYCN stock worth over $0. In addition, she makes $142,503 as Independent Director at Cyclerion Therapeutics.

Ms. Lovell CYCN stock SEC Form 4 insiders trading

Stephanie has made over 1 trades of the Cyclerion Therapeutics stock since 2022, according to the Form 4 filled with the SEC. Most recently she exercised 10,557 units of CYCN stock worth $481,082 on 22 November 2022.

The largest trade she's ever made was exercising 10,557 units of Cyclerion Therapeutics stock on 22 November 2022 worth over $481,082. On average, Stephanie trades about 960 units every 0 days since 2019. As of 22 November 2022 she still owns at least 5,657 units of Cyclerion Therapeutics stock.

You can see the complete history of Ms. Lovell stock trades at the bottom of the page.





Stephanie Lovell biography

Stephanie Lovell serves as Independent Director of the Company. She has served as a member of our Board of Directors since we commenced operations as an independent company in April 2019. Ms. Lovell has served as the executive vice president, Medicare and chief legal officer for Blue Cross Blue Shield of Massachusetts, Inc., or BCBSMA, since July 2015. Ms. Lovell previously served as the senior vice president and general counsel of BCBSMA from December 2011 to July 2015. Prior to BCBSMA, Ms. Lovell was the senior vice president of administration and general counsel for Boston Medical Center from March 2007 to December 2011. She also previously served as the first assistant attorney general in the Massachusetts Office of the Attorney General and as the executive director for the Massachusetts State Ethics Commission. Ms. Lovell currently serves as a director of the New England Law Foundation and The Partnership, Inc., and as a trustee of the Massachusetts Taxpayers Foundation. She also is a member of the investment committee of Goodwill Industries of Massachusetts. Ms. Lovell received a B.A. in philosophy from Hamilton College and a J.D. from Boston University School of Law.

What is the salary of Stephanie Lovell?

As the Independent Director of Cyclerion Therapeutics, the total compensation of Stephanie Lovell at Cyclerion Therapeutics is $142,503. There are 7 executives at Cyclerion Therapeutics getting paid more, with Andreas Busch having the highest compensation of $3,251,110.



How old is Stephanie Lovell?

Stephanie Lovell is 60, she's been the Independent Director of Cyclerion Therapeutics since 2019. There are 6 older and 8 younger executives at Cyclerion Therapeutics. The oldest executive at Cyclerion Therapeutics, Inc. is George Conrades, 81, who is the Independent Director.

What's Stephanie Lovell's mailing address?

Stephanie's mailing address filed with the SEC is C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, ANDOVER, MA, 01810.

Insiders trading at Cyclerion Therapeutics

Over the last 6 years, insiders at Cyclerion Therapeutics have traded over $240,273 worth of Cyclerion Therapeutics stock and bought 4,653,203 units worth $33,009,775 . The most active insiders traders include Peter M Hecht, Mark G Currie et Terrance Mcguire. On average, Cyclerion Therapeutics executives and independent directors trade stock every 84 days with the average trade being worth of $749,841. The most recent stock trade was executed by Terrance Mcguire on 9 August 2023, trading 8 units of CYCN stock currently worth $27.



What does Cyclerion Therapeutics do?

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.



What does Cyclerion Therapeutics's logo look like?

Cyclerion Therapeutics, Inc. logo

Complete history of Ms. Lovell stock trades at TransMedics et Cyclerion Therapeutics

Date
#
Société
 Initié
Trans.
Transaction
 Actions Prix par action Prix ​​total Actions après Source
22 Nov 2022 TMDX TransMedics Group, Inc. Stephanie Lovell
Exercice d'option 10,557 $45.57 $481,082
22 Nov 2022
5,657 ↗


Cyclerion Therapeutics executives and stock owners

Cyclerion Therapeutics executives and other stock owners filed with the SEC include: